Tuberculosis Research and Development: 2011 Report on Tuberculosis Research Funding trends, 2005-2010 – 2nd Edition
By Eleonora Jiménez-Levi
March 2012 – This is the 2nd Edition of the Treatment Action Group and Stop TB Partnership’s 2011 report on funding trends for tuberculosis (TB) research and development (R&D) from the baseline year 2005 through 2010, the last year for which full data is available. Updates to this report include new funding figures from the Canadian Institutes for Health Research, the Global Fund to Fight AIDS, TB, and Malaria, and Company Y; as well as revised data from Pfizer and the European Commission. In total, these donors reported an additional $13.4 million in TB R&D funding for 2010.
The 2011 second edition report finds 82 donors invested $630.4 million in TB R&D in 2010—a 76% increase over 2005 levels but only a 2% increase since 2009—the smallest increase ever documented by TAG. Of the 82 donors, the top ten accounted for 80%, or $506.4 million, of the global total. Nineteen new donors were captured in this year’s report, including three that invested at least $1 million in TB drugs and operational research.
With six years of comprehensive data, Tuberculosis Research and Development: 2011 Report on Tuberculosis Research Funding trends, 2005-2010 documents global progress against funding targets set by the Stop TB Partnership in 2006 in the Global Plan to Stop TB: 2006-2015, a 10 year implementation and research strategy to eliminate TB as a global health threat by 2050. The report offers year-to-year data on the leading TB research donors and analyzes funding trends across six TB research categories and four donor sectors. Most important, the report examines the state of TB research funding and underscores the urgency of adequate and sustained funding to produce the powerful new tools the world needs to eliminate TB as a public health threat by 2050.
To see reports from previous years, please click on the sidebar menu.